Cao Zeya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cao Zeya has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Deepika Kanojia
Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore
2 shared publications - H. Phillip Koeffler
Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore
2 shared publications - Pavithra Shyamsunder
Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore
2 shared publications - Pushkar Dakle
Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore
2 shared publications - Shree Pooja Sridharan
Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore
2 shared publications - Sin Tiong Ong
Cancer & Stem Cell Biology programme, Duke-NUS Medical School, Singapore 169857, Singapore
2 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5312
Correction: Shyamsunder et al. THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. Int. J. Mol. Sci. 2022, 23, 1207
- 12 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5312
Open AccessCorrection: Shyamsunder et al. THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. Int. J. Mol. Sci. 2022, 23, 1207
- Open Access
- 21 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1207
THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
Multiple myeloma (MM) is a hematological disease marked by abnormal growth of B cells in bone marrow. Inherent chromosomal instability and DNA damage are major hallmarks of MM, which implicates an aberrant DNA repair mechanism. Studies have implicated a role for CDK12 in the control of expression of DNA damage response genes. In this study, we examined the effect of a small molecule inhibitor of CDK12–THZ531 on MM cells. Treatment of MM cells with THZ531 led to heightened cell death accompanied by an extensive effect on gene expression changes. In particular, we observed downregulation of genes involved in DNA repair pathways. With this insight, we extended our study to identify synthetic lethal mechanisms that could be exploited for the treatment of MM cells. Combination of THZ531 with either DNA-PK inhibitor (KU-0060648) or PARP inhibitor (Olaparib) led to synergistic cell death. In addition, combination treatment of THZ531 with Olaparib significantly reduced tumor burden in animal models. Our findings suggest that using a CDK12 inhibitor in combination with other DNA repair inhibitors may establish an effective therapeutic regimen to benefit myeloma patients.
- 21 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1207
Open AccessTHZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
Multiple myeloma (MM) is a hematological disease marked by abnormal growth of B cells in bone marrow. Inherent chromosomal instability and DNA damage are major hallmarks of MM, which implicates an aberrant DNA repair mechanism. Studies have implicated a role for CDK12 in the control of expression of DNA damage response genes. In this study, we examined the effect of a small molecule inhibitor of CDK12–THZ531 on MM cells. Treatment of MM cells with THZ531 led to heightened cell death accompanied by an extensive effect on gene expression changes. In particular, we observed downregulation of genes involved in DNA repair pathways. With this insight, we extended our study to identify synthetic lethal mechanisms that could be exploited for the treatment of MM cells. Combination of THZ531 with either DNA-PK inhibitor (KU-0060648) or PARP inhibitor (Olaparib) led to synergistic cell death. In addition, combination treatment of THZ531 with Olaparib significantly reduced tumor burden in animal models. Our findings suggest that using a CDK12 inhibitor in combination with other DNA repair inhibitors may establish an effective therapeutic regimen to benefit myeloma patients.